Imagine discovering that a simple genetic test could save thousands of lives, yet it remains out of reach for most people. That’s the stark reality for one in 50 young Australians who unknowingly carry a high-risk genetic variant. A groundbreaking pilot study by Monash University has exposed a critical gap in our healthcare system, sparking urgent calls for action. But here’s where it gets controversial: despite the life-saving potential, three-quarters of those at risk don’t qualify for publicly funded genomic screening. Why? And what can we do about it?
The DNA Screen pilot study, conducted from 2022 to 2024, involved over 10,000 Australians aged 18 to 40. What’s truly staggering is that more than 30,000 people signed up within just one day of national media coverage, highlighting the public’s hunger for this kind of testing. The study was meticulously designed to ensure diverse representation, including participants from rural areas, culturally and linguistically diverse (CALD) communities, and Indigenous Australians. The cohort was 45.5% male, 30% CALD (with 24% born overseas and 18% from non-English-speaking households), and 2.2% Indigenous, with a median age of 31.9 years.
Here’s the part most people miss: the study identified pathogenic or likely pathogenic variants (PLPVs) in 2% of participants. Of the 165 who sought clinical genetic appointments, a shocking 75% were ineligible for publicly funded testing. As the study’s authors pointed out, ‘Most individuals with PLPVs in the general population remain unidentified, even for conditions that are commonly tested and medically actionable.’ This raises a critical question: Are we failing those who could benefit most from early intervention?
The study focused on 10 genes linked to hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolaemia—conditions the U.S. Centers for Disease Control and Prevention (CDC) has labeled as tier one, meaning they’re medically actionable but often underdiagnosed. The CDC proposed these as a starting point for adult genomic screening back in 2020, yet Australia lags behind. And while private genetic testing exists, concerns about accuracy, cost, and lack of follow-up care have left many hesitant. Combined with the DNA Screen findings, the need for a national screening program has never been clearer.
Monash University has launched a campaign urging Australians to email their Federal MPs to support funding for this initiative. Dr. Jane Tiller, project co-lead and genomic expert, framed it bluntly: ‘This is a matter of life or death for thousands of Australians.’ She emphasized the need to use genomic information proactively to prevent disease, not just treat it. But here’s the controversial angle: How do we balance the cost of widespread screening with the potential long-term savings of preventing serious illnesses? Is it fair to limit access based on current eligibility criteria, or should this be a universal right?
The Department of Health, Disability, and Ageing acknowledged the study and confirmed receipt of the funding proposal. However, they remained tight-lipped on when—or even if—a decision will be made. Health Minister Mark Butler has yet to comment, leaving advocates and the public in limbo. This isn’t just a scientific issue; it’s a moral one. Shouldn’t every Australian have the chance to know their genetic risks and take action?
What do you think? Is a national genomic screening program a necessity or a luxury? Should the government prioritize this funding, even if it means reallocating resources from other areas? Share your thoughts in the comments—this is a conversation we can’t afford to ignore.
